Sugi Predict

Sugi Predict / Compounds / SCHEMBL1007742

SCHEMBL1007742

SCHEMBL1007742

O=C(O)C(CC1CCCC1)n1ncc(Oc2cccnc2)cc1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR132 Q9UNW8 1/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.39
▸ ABL1 P00519 1/20 0.37
▸ EGLN2 Q96KS0 1/20 0.37
▸ EGLN1 Q9GZT9 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ GCK P35557 2/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ NPY5R Q15761 1/20 0.35
▸ ITGB3 P05106 1/20 0.35
▸ ITGAV P06756 1/20 0.35
▸ FFAR1 O14842 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CHRNB4 P30926 2/20 0.35
▸ CHRNA3 P32297 2/20 0.35
▸ CHRNB2 P17787 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1009307 0.91 NPY5R (0.43) GPR132HRH3EGLN1NPY5RFFAR1
SCHEMBL1008862 0.88 NPY5R (0.41) GPR132EGLN1NPY5RMEN1KMT2A
SCHEMBL1008428 0.85 ABL1 (0.38) HRH3ABL1FFAR4
SCHEMBL1008255 0.85 CTSS (0.39) HRH3GCKRAB9ANPY5R
SCHEMBL1007921 0.83 NPBWR1 (0.44) GCKRAB9ANPY5RFFAR1
SCHEMBL1008902 0.82 GCK (0.38) GPR132GCK
SCHEMBL1007983 0.82 P2RX3 (0.39) GPR132GCKFFAR4
SCHEMBL1008797 0.82 PPARG (0.39) GCKFFAR4FFAR1
SCHEMBL1009338 0.82 NR2F2 (0.39) GPR132RAB9AKMT2AKDM4E
SCHEMBL1008789 0.82 KCNH2 (0.40) GPR132ABL1LMNATDP1GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK GPR132 1022/4885HRH3 4306/4885ABL1 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.